{"id":69325,"date":"2026-07-03T15:07:38","date_gmt":"2026-07-03T07:07:38","guid":{"rendered":"https:\/\/flcube.com\/?p=69325"},"modified":"2026-07-03T15:07:39","modified_gmt":"2026-07-03T07:07:39","slug":"edding-genors-trispecific-antibody-gb268-secures-nmpa-ind-approval-for-phase-ib-ii-breast-cancer-trial-targeting-tnbc-and-hr-her2-subtypes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69325","title":{"rendered":"Edding Genor&#8217;s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\/II Breast Cancer Trial, Targeting TNBC and HR+\/HER2- Subtypes"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Edding Genor Group Holdings Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6998:HKG\">HKG: 6998<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved the <strong>Investigational New Drug (IND)<\/strong> application for <strong>GB268<\/strong>, a <strong>highly differentiated PD-1\/CTLA-4\/VEGF trispecific antibody<\/strong>, for a <strong>Phase Ib\/II clinical trial<\/strong> in patients with <strong>locally advanced unresectable or metastatic breast cancer<\/strong>. The trial will specifically evaluate GB268 in both <strong>triple-negative breast cancer (TNBC)<\/strong> and <strong>hormone receptor-positive\/HER2-negative (HR+\/HER2-) breast cancer<\/strong> subtypes.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Investigational New Drug (IND) Application<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GB268 \u2013 PD-1\/CTLA-4\/VEGF trispecific antibody<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase Ib\/II<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Locally advanced unresectable or metastatic breast cancer<\/td><\/tr><tr><td><strong>Subtypes<\/strong><\/td><td>Triple-negative breast cancer (TNBC) and HR+\/HER2-negative breast cancer<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>2 July 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-innovation\" class=\"wp-block-heading\">Drug Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> <strong>Trispecific antibody<\/strong> simultaneously targeting <strong>PD-1, CTLA-4, and VEGF<\/strong> pathways<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Integrated approach combining immune checkpoint inhibition (PD-1\/CTLA-4) with anti-angiogenic activity (VEGF)<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> First-in-class trispecific design addressing multiple tumor microenvironment mechanisms simultaneously<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Advancing from Phase I monotherapy data to Phase Ib\/II combination evaluation<\/li>\n\n\n\n<li><strong>Innovation Status:<\/strong> Highly differentiated platform technology with potential applicability across multiple solid tumors<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-phase-i-clinical-data-highlights\" class=\"wp-block-heading\">Phase I Clinical Data Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Result<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Maximum Tolerated Dose<\/strong><\/td><td>Not reached at 30 mg\/kg<\/td><td>Indicates wide therapeutic window<\/td><\/tr><tr><td><strong>Dose-Limiting Toxicities (DLTs)<\/strong><\/td><td>None observed up to 30 mg\/kg<\/td><td>Excellent safety profile compared to standard checkpoint inhibitors<\/td><\/tr><tr><td><strong>Antitumor Activity<\/strong><\/td><td>Favorable results demonstrated<\/td><td>Promising efficacy signals warranting further development<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable across dose escalation<\/td><td>Supports potential for combination regimens and higher dosing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-trial-design-amp-strategic-focus\" class=\"wp-block-heading\">Clinical Trial Design &amp; Strategic Focus<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Patient Population<\/strong><\/td><td>Locally advanced unresectable or metastatic breast cancer<\/td><\/tr><tr><td><strong>Key Subtypes<\/strong><\/td><td><strong>TNBC<\/strong> (aggressive, limited treatment options) and <strong>HR+\/HER2-<\/strong> (largest breast cancer segment)<\/td><\/tr><tr><td><strong>Trial Structure<\/strong><\/td><td>Phase Ib\/II seamless design enabling rapid dose optimization and efficacy evaluation<\/td><\/tr><tr><td><strong>Therapeutic Gap<\/strong><\/td><td>Addresses significant unmet needs in both subtypes, particularly TNBC with poor prognosis<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Novel trispecific approach differentiates from existing monospecific and bispecific antibodies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-amp-strategic-significance\" class=\"wp-block-heading\">Market Opportunity &amp; Strategic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>TNBC Market Need<\/strong><\/td><td>Represents 15-20% of breast cancers with limited targeted therapy options<\/td><\/tr><tr><td><strong>HR+\/HER2- Prevalence<\/strong><\/td><td>Accounts for ~65% of all breast cancer cases, largest therapeutic segment<\/td><\/tr><tr><td><strong>Trispecific Platform Validation<\/strong><\/td><td>Success would validate Edding Genor&#8217;s proprietary multispecific antibody technology<\/td><\/tr><tr><td><strong>China Biotech Innovation<\/strong><\/td><td>Demonstrates advancement beyond biosimilars to complex novel biologics<\/td><\/tr><tr><td><strong>Global Potential<\/strong><\/td><td>Trispecific approach could have international applicability if successful<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-forward-outlook\" class=\"wp-block-heading\">Forward Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The NMPA IND approval positions Edding Genor to advance a potentially transformative therapy for two major breast cancer subtypes with substantial unmet medical needs. By simultaneously targeting three critical pathways\u2014immune checkpoints PD-1 and CTLA-4, plus angiogenesis through VEGF\u2014the company aims to overcome limitations of single-target approaches and improve outcomes for patients with aggressive disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The favorable Phase I safety profile, with no dose-limiting toxicities even at 30 mg\/kg, suggests GB268 may offer a superior therapeutic index compared to existing checkpoint inhibitors. This could enable more aggressive dosing strategies and combination approaches while maintaining manageable toxicity profiles.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Success in this trial would not only address critical gaps in breast cancer treatment but also validate Edding Genor&#8217;s trispecific antibody platform for potential expansion into other solid tumor indications. The company plans to leverage its established clinical development capabilities and partnerships with leading Chinese oncology centers to accelerate patient enrollment and data generation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and therapeutic potential. Actual results may differ due to risks including clinical trial outcomes, safety findings, competitive dynamics, and regulatory decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Edding Genor Group Holdings Limited (HKG: 6998) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69327,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,957,953,28],"class_list":["post-69325","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-edding-genor","tag-hkg-6998","tag-multi-specific-antibodies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Edding Genor&#039;s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\/II Breast Cancer Trial, Targeting TNBC and HR+\/HER2- Subtypes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Edding Genor Group Holdings Limited (HKG: 6998) announced that China&#039;s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for GB268, a highly differentiated PD-1\/CTLA-4\/VEGF trispecific antibody, for a Phase Ib\/II clinical trial in patients with locally advanced unresectable or metastatic breast cancer. The trial will specifically evaluate GB268 in both triple-negative breast cancer (TNBC) and hormone receptor-positive\/HER2-negative (HR+\/HER2-) breast cancer subtypes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69325\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Edding Genor&#039;s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\/II Breast Cancer Trial, Targeting TNBC and HR+\/HER2- Subtypes\" \/>\n<meta property=\"og:description\" content=\"Edding Genor Group Holdings Limited (HKG: 6998) announced that China&#039;s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for GB268, a highly differentiated PD-1\/CTLA-4\/VEGF trispecific antibody, for a Phase Ib\/II clinical trial in patients with locally advanced unresectable or metastatic breast cancer. The trial will specifically evaluate GB268 in both triple-negative breast cancer (TNBC) and hormone receptor-positive\/HER2-negative (HR+\/HER2-) breast cancer subtypes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69325\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-03T07:07:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-03T07:07:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0303.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69325#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69325\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Edding Genor&#8217;s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\\\/II Breast Cancer Trial, Targeting TNBC and HR+\\\/HER2- Subtypes\",\"datePublished\":\"2026-07-03T07:07:38+00:00\",\"dateModified\":\"2026-07-03T07:07:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69325\"},\"wordCount\":608,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69325#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0303.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Edding Genor\",\"HKG: 6998\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69325#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69325\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69325\",\"name\":\"Edding Genor's Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\\\/II Breast Cancer Trial, Targeting TNBC and HR+\\\/HER2- Subtypes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69325#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69325#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0303.webp\",\"datePublished\":\"2026-07-03T07:07:38+00:00\",\"dateModified\":\"2026-07-03T07:07:39+00:00\",\"description\":\"Edding Genor Group Holdings Limited (HKG: 6998) announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for GB268, a highly differentiated PD-1\\\/CTLA-4\\\/VEGF trispecific antibody, for a Phase Ib\\\/II clinical trial in patients with locally advanced unresectable or metastatic breast cancer. The trial will specifically evaluate GB268 in both triple-negative breast cancer (TNBC) and hormone receptor-positive\\\/HER2-negative (HR+\\\/HER2-) breast cancer subtypes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69325#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69325\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69325#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0303.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0303.webp\",\"width\":1080,\"height\":608,\"caption\":\"Edding Genor's Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\\\/II Breast Cancer Trial, Targeting TNBC and HR+\\\/HER2- Subtypes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69325#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Edding Genor&#8217;s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\\\/II Breast Cancer Trial, Targeting TNBC and HR+\\\/HER2- Subtypes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Edding Genor's Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\/II Breast Cancer Trial, Targeting TNBC and HR+\/HER2- Subtypes - Insight, China&#039;s Pharmaceutical Industry","description":"Edding Genor Group Holdings Limited (HKG: 6998) announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for GB268, a highly differentiated PD-1\/CTLA-4\/VEGF trispecific antibody, for a Phase Ib\/II clinical trial in patients with locally advanced unresectable or metastatic breast cancer. The trial will specifically evaluate GB268 in both triple-negative breast cancer (TNBC) and hormone receptor-positive\/HER2-negative (HR+\/HER2-) breast cancer subtypes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69325","og_locale":"en_US","og_type":"article","og_title":"Edding Genor's Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\/II Breast Cancer Trial, Targeting TNBC and HR+\/HER2- Subtypes","og_description":"Edding Genor Group Holdings Limited (HKG: 6998) announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for GB268, a highly differentiated PD-1\/CTLA-4\/VEGF trispecific antibody, for a Phase Ib\/II clinical trial in patients with locally advanced unresectable or metastatic breast cancer. The trial will specifically evaluate GB268 in both triple-negative breast cancer (TNBC) and hormone receptor-positive\/HER2-negative (HR+\/HER2-) breast cancer subtypes.","og_url":"https:\/\/flcube.com\/?p=69325","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-03T07:07:38+00:00","article_modified_time":"2026-07-03T07:07:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0303.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69325#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69325"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Edding Genor&#8217;s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\/II Breast Cancer Trial, Targeting TNBC and HR+\/HER2- Subtypes","datePublished":"2026-07-03T07:07:38+00:00","dateModified":"2026-07-03T07:07:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69325"},"wordCount":608,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69325#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0303.webp","keywords":["Clinical trial approval \/ initiation","Edding Genor","HKG: 6998","Multi-specific antibodies"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69325#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69325","url":"https:\/\/flcube.com\/?p=69325","name":"Edding Genor's Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\/II Breast Cancer Trial, Targeting TNBC and HR+\/HER2- Subtypes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69325#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69325#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0303.webp","datePublished":"2026-07-03T07:07:38+00:00","dateModified":"2026-07-03T07:07:39+00:00","description":"Edding Genor Group Holdings Limited (HKG: 6998) announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for GB268, a highly differentiated PD-1\/CTLA-4\/VEGF trispecific antibody, for a Phase Ib\/II clinical trial in patients with locally advanced unresectable or metastatic breast cancer. The trial will specifically evaluate GB268 in both triple-negative breast cancer (TNBC) and hormone receptor-positive\/HER2-negative (HR+\/HER2-) breast cancer subtypes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69325#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69325"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69325#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0303.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0303.webp","width":1080,"height":608,"caption":"Edding Genor's Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\/II Breast Cancer Trial, Targeting TNBC and HR+\/HER2- Subtypes"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69325#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Edding Genor&#8217;s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib\/II Breast Cancer Trial, Targeting TNBC and HR+\/HER2- Subtypes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0303.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69325"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69325\/revisions"}],"predecessor-version":[{"id":69328,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69325\/revisions\/69328"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69327"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}